Peptonic Medical AB (publ) ("Peptonic" or "the Company") is launching a new product segment within health and beauty. This initiative represents a significant broadening of the Company's product portfolio and constitutes an important step in the long-term strategy to create new revenue streams and strengthen the market position. The launch is planned for the second half of 2026. In connection with this, the Company will also bring products together under a new common brand in accordance with the strategic development plan.
The first product will be an innovative dietary supplement developed as part of Peptonic Medical's long-term strategy to broaden its offering within women's health and beauty. As part of strengthening and complementing the product portfolio, the Company has also expanded the range with two new products ahead of upcoming launches: intimate wipes and a moisturising intimate cream.
The dietary supplement is a functional beauty blend powder that combines collagen peptides with carefully selected vitamins, minerals and active ingredients. The formula is designed to support skin structure, hair and nails, as well as contribute to energy and general well-being. The product contains, among other things, vitamin C, which contributes to normal collagen formation; biotin and zinc, which help maintain normal hair, skin and nails; hyaluronic acid for skin hydration; and red maca - a plant-based ingredient traditionally associated with hormonal balance.
By addressing needs that arise during different hormonal phases, the product has been developed as a daily dietary supplement for women throughout their hormonal journey. The launch also strengthens the Company's position with a new brand and a broader target audience.
- The launch marks an important strategic step for Peptonic. We are now entering an attractive and fast-growing market segment where demand for products that combine beauty, health and well-being continues to rise globally. By establishing a new product segment and simultaneously bringing products together under a new brand, we are creating the conditions for increased market presence, stronger customer loyalty and long-term growth. We believe this initiative offers us excellent opportunities to reach new customer groups and strengthen our position within women's health and beauty," says Daniel Rudeklint, interim CEO of Peptonic Medical AB.
The launch represents a further step in the Company's long-term ambition to develop innovative products with a focus on wellbeing, quality of life and beauty.
For further information, please contact:
Daniel Rudeklint, interim CEO of Peptonic Medical AB
Email:daniel.rudeklint@peptonicmedical.se
Telephone: +46 73 158 02 73
About Peptonic Medical AB
Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products for women's intimate health. Under the VagiVital and Vernivia brands, the Company offers a range of effective and gentle over-the-counter products that help women understand, treat and prevent common gynaecological conditions. Peptonic's growth strategy is based on geographical expansion, particularly in the US and Europe, and on continuously strengthening the product portfolio through in-house product development and strategic acquisitions.